甘李药业股份有限公司2025年年度业绩预增公告

Core Viewpoint - Gann Li Pharmaceutical Co., Ltd. expects significant growth in net profit for the year 2025, projecting an increase of 50% or more compared to the previous year, driven by domestic and international revenue growth and equity transfer gains [2][8]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of 1.1 billion to 1.2 billion yuan for 2025, representing an increase of 485 million to 585 million yuan, or a year-on-year growth of 78.96% to 95.23% [2][4]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between 700 million and 800 million yuan, an increase of 270 million to 370 million yuan, translating to a year-on-year growth of 62.63% to 85.86% [2][4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was 630.39 million yuan, with a net profit attributable to shareholders of 614.66 million yuan, and a net profit excluding non-recurring gains and losses of 430.43 million yuan [6]. Group 3: Reasons for Profit Increase - The anticipated profit increase is attributed to enhanced market coverage and sales growth in insulin products within the domestic market, as well as successful international expansion efforts in emerging markets along the Belt and Road Initiative [8]. - The company has completed the first phase of a two-step equity transfer agreement with Guangdong Hengqin Ganlin Enterprise Management Co., Ltd., transferring 55% of its subsidiary, Gan Medical Technology Jiangsu Co., Ltd., which has contributed to increased investment income [9].